This is the new website of the UP MS.  |  Back to the old website

  All colleagues of the unit

SÁRSZEGI, Zsolt

SÁRSZEGI, Zsolt

senior lecturer

Heart Institute

Telefon: *0618, 34687

Supervisor of the following TDK topics

Supervisor: SÁRSZEGI, Zsolt

Co-supervisor: Dr. SZABÓ, Dóra

Sportcardiology is a popular and important topic in these days through the increasing incidence of sudden cardiac death by the young and „healthy” sportsmen. In most cases the cause of sudden cardiac death is an occult cardiac disease. A lot of researches have already shown the differences between the phisiological sport heart and pathological cardiac conditions. In this study we examine sportsmen competing in different sport arts. Special ECG, particular echocardiographic examination furthermore spiroergometry are performing. The sportsmen with pathological results have a heart MRI examination, too. The aim of our examination is to compare the results of different (static or dinamic) sports and to configure a relative fast screening method for the everyday routine of sportsmen’s screening.

Supervisor: SÁRSZEGI, Zsolt

Co-supervisor: Dr. TAMÁS, Andrea

Pituitary adenylate cyclase activating polypeptide (PACAP) is a multifunctional neuropeptide having cardioprotective effects in various animal models. We have already shown PAC1 receptors in human heart muscles, and detected that PACAP38-LI and PACAP27-LI are significantly higher in ischemic heart diseases compared with valvular abnormalities in heart tissue samples. Based on the results of the animal experiments of the last decades we assumed that PACAP might have a protective effect against ischemic injury due to its antiapoptotic effect. Moreover, several studies have already proven that there may be a significant correlation between PACAP and the severity of heart failure; furthermore as an antiapoptotic polypeptide, it can influence the progression of heart failure. Based on all of these results we examine cardiac disorders with the etiology of ischemia (such as acute myocardial infarct, ischemic heart disease) and heart failure, furthermore we are going to detect the changes of serum PACAP levels due to the different therapies. ELISA method is used to quantify the PACAP levels in human plasma. With these researches there will be known more details about the exact role of PACAP in the pathomechanism and progression of several cardiac diseases, so it might be a potential biomarker in the future.